Pharmacokinetics/pharmacodynamics (PK/PD) approach in the veterinary medicine

被引:0
|
作者
Somogyi Zoltan [1 ]
Karancsi Zita [1 ]
Jerzsele Akos [1 ]
机构
[1] ATE Gyagyszertani & Meregtani Tanszek, Szeged, Hungary
关键词
PHARMACOKINETICS; FLORFENICOL; DOXYCYCLINE;
D O I
暂无
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Among veterinary drugs, antibacterial drugs are frequently used in the clinical practice. The aim of antibacterial therapy is to enhance clinical outcome and eliminate pathogenic microbes. Antibacterial pharmacokinetic/pharmacodynamic (PK/PD) relationship reflects a correlation between the antibacterial drug concentration in the blood, the concentration of biologically active drug at the site of the infection, and the sensitivity of the microbe. The PK parameters, such as AUC and C-max, describe the fate of the drug in the host. The PD parameters, such as MIC, describe the inhibitory effect of the drug on bacterial pathogens. The three most frequently used PK/PD indices are ratio of area under the concentration time curve at 24 h to the MIC (AUC(0-24)/MIC), the ratio of the peak drug concentration to the MIC (C-max/MIC), and the percentage of the dosing interval for which the plasma concentration exceeds the MIC (%T > MIC). Using of PK/PD approach in veterinary medicine can optimize the right dosing regimen. Therefore, reduced toxicity and reduction in the incidence of resistance are important consequences. The emergence of resistance is a global issue in human and veterinary medicine alike. The aim of this review is to introduce PK/PD relationships in veterinary medicine based on in vitro and in vivo models.
引用
收藏
页码:37 / 46
页数:10
相关论文
共 50 条
  • [21] The Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, and Tolerability of JNJ-42165279, a Potent and Selective Inhibitor of Fatty Acid Amide Hydrolase (FAAH) in Healthy Subjects
    Zannikos, Peter
    Wennerholm, Michelle
    Van Der Ark, Peter
    Vaccaro, Nicole
    Schmidt, Mark
    Rassnick, Stefanie
    Pemberton, Darrel
    Palmer, James
    Bredt, David
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S453 - S454
  • [22] Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods
    Liu, Dongyang
    Ma, Xifeng
    Liu, Yang
    Zhou, Huimin
    Shi, Chongtie
    Wu, Frank
    Jiang, Ji
    Hu, Pei
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 89 : 73 - 82
  • [23] A personalised approach to antibiotic pharmacokinetics and pharmacodynamics in critically ill patients
    Heffernan, Aaron J.
    Lim, Sazlyna Mohd Sazlly
    Lipman, Jeffrey
    Roberts, Jason A.
    ANAESTHESIA CRITICAL CARE & PAIN MEDICINE, 2021, 40 (06)
  • [24] Therapeutic Drug Monitoring and Individualized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics
    He, Shiyu
    Bian, Jialu
    Shao, Qianhang
    Zhang, Ying
    Hao, Xu
    Luo, Xingxian
    Feng, Yufei
    Huang, Lin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [26] PHARMACOKINETICS AND PHARMACODYNAMICS OF AMLODIPINE
    ABERNETHY, DR
    CARDIOLOGY, 1992, 80 : 31 - 36
  • [27] Pharmacokinetics and pharmacodynamics in the newborn
    Eberini, I.
    VETERINARY RESEARCH COMMUNICATIONS, 2008, 32 (Suppl 1) : S77 - S80
  • [28] Macrolides: pharmacokinetics and pharmacodynamics
    Van Bambeke, F
    Tulkens, PM
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 18 : S17 - S23
  • [29] Pharmacokinetics and pharmacodynamics of suxamethonium
    Torda, TA
    Graham, GG
    Warwick, NR
    Donohue, P
    ANAESTHESIA AND INTENSIVE CARE, 1997, 25 (03) : 272 - 278
  • [30] Pharmacokinetics and pharmacodynamics of azosemide
    Suh, OK
    Kim, SH
    Lee, MG
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2003, 24 (07) : 275 - 297